Keros Therapeutics, Inc. (NASDAQ:KROS) Position Increased by American Century Companies Inc.

American Century Companies Inc. lifted its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 10.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 328,920 shares of the company's stock after buying an additional 31,251 shares during the quarter. American Century Companies Inc. owned approximately 0.81% of Keros Therapeutics worth $5,207,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Swiss National Bank grew its stake in Keros Therapeutics by 4.8% in the 4th quarter. Swiss National Bank now owns 59,000 shares of the company's stock worth $934,000 after acquiring an additional 2,700 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Keros Therapeutics in the fourth quarter valued at $461,000. AlphaQuest LLC increased its stake in Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after purchasing an additional 2,964 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Keros Therapeutics by 7.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 279,682 shares of the company's stock worth $4,427,000 after buying an additional 19,562 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in Keros Therapeutics by 2.6% in the 4th quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company's stock worth $1,549,000 after buying an additional 2,462 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

KROS has been the topic of several recent analyst reports. Cantor Fitzgerald lowered shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. BTIG Research lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, December 12th. Wells Fargo & Company dropped their price objective on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, February 27th. Wedbush reaffirmed a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Finally, Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Keros Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $40.33.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock traded up $0.57 during trading on Wednesday, reaching $10.33. The company had a trading volume of 2,701,348 shares, compared to its average volume of 742,191. The company has a market cap of $419.01 million, a price-to-earnings ratio of -1.98 and a beta of 1.39. Keros Therapeutics, Inc. has a fifty-two week low of $9.14 and a fifty-two week high of $72.37. The firm's fifty day moving average is $10.86 and its 200-day moving average is $31.41.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. On average, research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.